SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021
July 28 2021 - 8:30AM
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the
“Company”), a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapies for a broad range of
indications, today announced that it will host a virtual investor
symposium on its lead asset, galinpepimut-S (GPS), on Tuesday,
August 17, 2021, from 1:00 p.m. to 2:00 p.m. ET.
The event will focus on the Company’s clinical
program for GPS, including additional details on its recently
released clinical data, as well as the significant unmet need in
acute myeloid leukemia (AML), the indication being studied in the
GPS Phase 3 REGAL study. SELLAS management will be joined by
leading cancer researcher, M. Yair Levy, M.D., Director of
Hematologic Malignancies at the Baylor University Medical Center,
and member of the REGAL Steering Committee.
Dr. Yair Levy serves as the Director of
Hematologic malignancies research and specializes in hematology,
including lymphoma, myeloma, and leukemia. Dr. Levy received his
medical doctorate from the University of Wisconsin at Madison
School of Medicine. He served his residency at the University of
Pittsburgh Medical Center and his hematology fellowship at Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore,
MD. He also served on the faculty at Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins. Dr. Levy has won several awards,
including the ASCO Merit Award, ASH Merit Award, Walsh Research
Grant, and the National Institutes of Health LRP Award.
Webcast InformationTo attend
the live video webcast, please register or email KCSA
Strategic Communications at SELLAS@kcsa.com.
About SELLAS Life Sciences Group,
Inc. SELLAS is a late-stage clinical biopharmaceutical
company focused on developing novel cancer immunotherapeutics for a
broad range of indications. SELLAS’ lead product candidate, GPS, is
licensed from Memorial Sloan Kettering Cancer Center and targets
the WT1 protein, which is present in an array of tumor types. GPS
has potential both as a monotherapy and in combination to address a
broad spectrum of hematologic malignancies and solid tumor
indications. SELLAS’ second product candidate, nelipepimut-S (NPS),
is a HER2-directed cancer immunotherapy with potential to treat
patients with early-stage breast cancer with low to intermediate
HER2 expression, otherwise known as HER2 1+ or 2+, which includes
triple negative breast cancer patients, following the standard of
care.For more information on SELLAS, please visit
www.sellaslifesciences.com.
Forward-Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, forward-looking statements can be identified by terminology
such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,”
“should,” “project,” “believe,” “estimate,” “predict,” “potential,”
“intend,” or “continue” and other words or terms of similar
meaning. These statements include, without limitation, statements
related to the clinical development of GPS and the potential for
GPS as a drug development candidate. These forward-looking
statements are based on current plans, objectives, estimates,
expectations, and intentions, and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with the COVID-19 pandemic and its impact
on the Company’s clinical plans, risks and uncertainties associated
with immune-oncology product development and clinical success
thereof, the uncertainty of regulatory approval, and other risks
and uncertainties affecting SELLAS and its development programs as
set forth under the caption “Risk Factors” in SELLAS’ Annual Report
on Form 10-K filed on March 23, 2021 and in its other SEC filings.
Other risks and uncertainties of which SELLAS is not currently
aware may also affect SELLAS’ forward-looking statements and may
cause actual results and the timing of events to differ materially
from those anticipated. The forward-looking statements herein are
made only as of the date hereof. SELLAS undertakes no obligation to
update or supplement any forward-looking statements to reflect
actual results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
Investor Contacts Valter Pinto
/ Allison SossKCSA Strategic CommunicationsEmail:
SELLAS@kcsa.comPhone: 914.907.2675 / 215.272.2707
Media Contacts Caitlin Kasunich
/ Raquel Cona KCSA Strategic Communications Email:
SELLAS@kcsa.comPhone: 212.896.1241 / 212.896.1276
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024